Finance

Beta
Lists
AMGN34:BVMF
Amgen Inc. BDR
R$64,09
0,00%
(0,00) 1D
10 ມິ.ຖ., 16 ໂມງ 56 ນາທີ 00 ວິນາທີ GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Open
R$64,06
High
R$64,09
Low
R$64,06
Mkt. cap
໑໘໒,໒໗ ຕື້
Avg. vol.
໗໒໕,໐໐
Volume
໖,໐໐
52-wk high
R$77,39
52-wk low
R$47,94
Shares outstanding
໕໓໙,໗໑ ລ້ານ
No. of employees
໓໒ ພັນ
Open
R$64,06
High
R$64,09
Low
R$64,06
Mkt. cap
໑໘໒,໒໗ ຕື້
Avg. vol.
໗໒໕,໐໐
Volume
໖,໐໐
52-wk high
R$77,39
52-wk low
R$47,94
Shares outstanding
໕໓໙,໗໑ ລ້ານ
No. of employees
໓໒ ພັນ
News stories
From sources across the web
MarketBeat
MarketBeat
·
3 ຊົ່ວໂມງກ່ອນ
ING Groep NV Buys New Shares in Amgen Inc. $AMGN
MarketWatch
MarketWatch
·
15 ຊົ່ວໂມງກ່ອນ
Amgen Inc. stock underperforms Wednesday when compared to competitors
Yahoo Finance
Yahoo Finance
·
23 ຊົ່ວໂມງກ່ອນ
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31,5 ພັນ
Founded8 ມ.ສ. 1980
Headquartersທາວຊັນ ໂອກ, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websiteamgen.com
Last report
30 ມ.ສ. 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
US$5,15 / US$4,77
+8,04%beat
Revenue / Est. (USD)
໘,໖໒ ຕື້ / ໘,໕໗ ຕື້
+0,55%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ມິ.ຖ. 2025
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
Revenue
9,18 ຕື້
9,56 ຕື້
9,87 ຕື້
8,62 ຕື້
Cost of goods sold
2,67 ຕື້
2,74 ຕື້
2,68 ຕື້
2,50 ຕື້
Cost of revenue
2,67 ຕື້
2,74 ຕື້
2,68 ຕື້
2,50 ຕື້
Research and development expenses
1,74 ຕື້
1,90 ຕື້
2,14 ຕື້
1,72 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,69 ຕື້
1,72 ຕື້
1,95 ຕື້
1,60 ຕື້
Operating expense
3,50 ຕື້
3,55 ຕື້
4,18 ຕື້
3,21 ຕື້
Total operating expenses
6,18 ຕື້
6,29 ຕື້
6,85 ຕື້
5,70 ຕື້
Operating income
3,00 ຕື້
3,26 ຕື້
3,01 ຕື້
2,91 ຕື້
Other non operating income
-113,00 ລ້ານ
181,00 ລ້ານ
143,00 ລ້ານ
192,00 ລ້ານ
EBT including unusual items
1,57 ຕື້
3,92 ຕື້
1,51 ຕື້
2,08 ຕື້
EBT excluding unusual items
2,37 ຕື້
2,72 ຕື້
2,51 ຕື້
2,37 ຕື້
Income tax expense
136,00 ລ້ານ
705,00 ລ້ານ
181,00 ລ້ານ
265,00 ລ້ານ
Effective tax rate
8,67%
17,98%
11,96%
12,72%
Other operating expenses
68,00 ລ້ານ
-71,00 ລ້ານ
82,00 ລ້ານ
-113,00 ລ້ານ
Net income
1,43 ຕື້
3,22 ຕື້
1,33 ຕື້
1,82 ຕື້
Net profit margin
15,60%
33,65%
13,51%
21,11%
Earnings per share
6,02
5,64
5,29
5,15
Interest and investment income
-
-
408,00 ລ້ານ
-
Interest expense
-694,00 ລ້ານ
-685,00 ລ້ານ
-1,06 ຕື້
-657,00 ລ້ານ
Net interest expenses
-694,00 ລ້ານ
-685,00 ລ້ານ
-653,00 ລ້ານ
-657,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
4,34 ຕື້
4,57 ຕື້
4,02 ຕື້
4,03 ຕື້
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more